Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis

Myasthenia gravis (MG) is a lifelong autoimmune disorder that affects neuromuscular transmission. The long-term treatment plan should include immunotherapy. We investigated the long-term safety and efficacy of tacrolimus for the treatment of MG in real-world clinical practice. We retrospectively rev...

Full description

Saved in:
Bibliographic Details
Published in:Yonsei medical journal 2019, 60(7), , pp.633-639
Main Authors: Kim, Yool Hee, Shin, Ha Young, Kim, Seung Min
Format: Article
Language:English
Subjects:
Original
의학일반
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myasthenia gravis (MG) is a lifelong autoimmune disorder that affects neuromuscular transmission. The long-term treatment plan should include immunotherapy. We investigated the long-term safety and efficacy of tacrolimus for the treatment of MG in real-world clinical practice. We retrospectively reviewed 160 MG patients treated with tacrolimus from 2005 to 2015. Myasthenia Gravis Foundation of America (MGFA) clinical classification, MGFA post-intervention status, myasthenic functional score, and dose of oral prednisolone were investigated. Adverse events occurred in 68 patients (42.5%), most of which were minor and well-managed. Clinical severity scales improved after administration of tacrolimus, compared to the baseline. Compared to 6 months before administration of tacrolimus, prednisolone dose significantly decreased at 12 months after treatment (2.85±0.92 mg/day, =0.002), 18 months after treatment (3.36±0.99 mg/day, =0.001), and 24 months after treatment (3.71±0.93 mg/day,
ISSN:0513-5796
1976-2437
DOI:10.3349/ymj.2019.60.7.633